Physician profile
Steven Soberman
NPI 1902905797
$1,010.51
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $152 · 2021: $130.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.99 | 2019-2021 | |
| Coloplast Corp | $138.82 | 2019-2020 | |
| Therapeuticsmd, INC. | $89.88 | 2019-2021 | |
| Astellas Pharma US INC | $84.79 | 2019-2021 | |
| Allergan, INC. | $78.73 | 2019-2020 | |
| Lupin INC. | $51.42 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.65 | 2019 | |
| Exeltis, USA INC. | $29.82 | 2019 | |
| Agile Therapeutics, INC. | $28.03 | 2021 | |
| Millicent US INC | $27.50 | 2019 | |
| Daiichi Sankyo INC. | $27.21 | 2020 | |
| Amag Pharmaceuticals, INC. | $22.41 | 2019 | |
| Duchesnay USA Incorporated | $14.44 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.37 | 2020 | |
| Mission Pharmacal Company | $14.26 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Soberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.